Novo Licenses Hengrui Once-Weekly Oral Incretin
Novo Nordisk licensed ex-China-region rights to Hengrui’s HRS-1596, a Phase 1-ready oral GLP-1/GIP dual-receptor agonist designed for once-weekly dosing in obesity and type 2 diabetes. Hengrui will receive $300 million upfront and may receive…
